Lancet Oncology APC and Open Access: High IF and High Price

This is the critical detail for Lancet Oncology's APC. Elsevier says Lancet journals are included in some of its open access agreements, not all of them.

In its hybrid journals, the Lancet Group offers open access to authors of research Articles through two routes.

The Lancet Group lists the funders it has arrangements with on its open access page, including Cancer Research UK, NIH, UKRI, the European Research Council and Wellcome. For institutional coverage, contact the Lancet open access team.

Check with your library specifically about Lancet coverage before assuming an Elsevier agreement applies.

The Lancet publishes multiple journals relevant to cancer researchers:

If your cancer paper has implications beyond oncology, the flagship Lancet is even more prestigious but harder to get into and more expensive for OA. eBioMedicine is a cheaper OA alternative within the Lancet ecosystem, though its scope is broader and its IF is lower.

Lancet Oncology doesn't have a direct gold OA companion journal in the way that Blood has Blood Advances or Hepatology has Hepatology Communications. If your paper doesn't reach Lancet Oncology's bar, the Lancet family doesn't offer a natural step-down within oncology specifically. You'd need to look at journals from other publishers.

The Lancet Group manages Lancet Oncology's waivers and discounts:

Research4Life discounts:

• If all authors are from HINARI group A countries, the paper is eligible for a full APC waiver.

• If all authors are from a group B country, or from a mix of group A and B countries, the paper is eligible for a 50% fee waiver.

Other waivers and discounts:

• Authors without institutional or funding body support for the APC can contact the Lancet Group once the paper is accepted, with information on their funders, the routes they have explored, and how much they can pay.

• The Lancet Group says the decision to accept or reject a paper is not related to ability to pay, and that editors do not have access to payment information upon submission.

Institutional agreements:

• Lancet journals are included in some of Elsevier's open access agreements; the Lancet Group asks authors to contact its team for details.

For well-funded oncology researchers at major cancer centers, the expectation is that NCI, ERC, or foundation grants cover the APC. The waiver system is designed for researchers who genuinely lack access to publication funds.

The Lancet Group lists the National Institutes of Health among the funders with which it has open access arrangements for its hybrid journals, and its green open access route lets authors deposit the final accepted version in any repository 6 months after publication.

If your funder requires CC BY, the Lancet Group offers it as a licence choice at the listed APC of USD 8,810, so check whether your funder or institution has an agreement that covers it. European researchers on ERC or national council grants should budget for this explicitly.

The Wellcome Trust and HHMI typically cover APCs directly through their OA funding programs. If you have Wellcome or HHMI funding, the APC is usually not a financial burden, but you need to arrange payment before the invoice arrives.

Understanding what Lancet Oncology publishes helps you assess whether the APC is a worthwhile investment:

• Phase III clinical trials in solid tumors and hematologic malignancies

• Practice-changing Phase II trials with strong endpoints

• Large meta-analyses and pooled analyses of clinical trial data

• Health policy and cancer care delivery research

• Cancer epidemiology with global public health implications

• Personal Views and Comments (the Lancet Group says the APC does not apply to Comments, Correspondence, or content directly commissioned by its editors)

The journal has a distinctly European editorial voice. European cooperative group trials are heavily represented. EORTC, ESMO-sponsored studies, and UK-based trials are core content. North American researchers publish there too, but the editorial gravity tilts toward Europe.

Competition is fierce, and the editors prioritize studies that will change clinical practice globally.

• License choice. The Lancet Group lists a single APC, and articles with commercial funding only must use CC BY-NC-ND. Check with your funder whether a specific licence is preferred.

• Check institutional coverage. Budget the full APC in your grant application unless your funder or institution has an agreement that covers The Lancet Oncology.

• Green open access timing. Authors who choose the green route can deposit the final accepted version in any repository 6 months after publication.

• Strict formatting and word limits. Lancet Oncology enforces tight word counts and structured formats.

• Extended data and appendix expectations. Large clinical trials are expected to submit extensive supplementary data, protocol documents, and statistical analysis plans.

For oncology researchers choosing where to submit, cost should be one factor among many:

1. Cost is your priority? JCO is free. It's the same tier of prestige. Submit there unless your paper is a better editorial fit for Lancet Oncology.

1. European cooperative group trial? Lancet Oncology is the natural home. Budget the listed APC of USD 8,810 for OA from your grant unless an agreement covers it.

1. Plan S funder? The Lancet Group does not mention Plan S, so check with your funder, and budget the listed APC of USD 8,810 for open access unless an agreement covers it.

1. NIH-funded? NIH is among the funders the Lancet Group lists for open access in its hybrid journals, so check the open access page, or use the green route and deposit the accepted version 6 months after publication.

1. Didn't get into Lancet Oncology? Annals of Oncology (IF ~80.4) and JAMA Oncology (IF ~23.9) are strong alternatives at lower prices.

Lancet Oncology's prestige is real. An IF of ~42 places it among the top five oncology journals worldwide, and its readership includes decision-makers in European oncology policy. For the right paper, the APC is justified. For papers that could go equally well to JCO, the cost difference is hard to ignore.

Before submitting, make sure your trial design, reporting standards (CONSORT, STROBE), and clinical framing meet Lancet Oncology's expectations. Lancet Oncology submission readiness check to catch issues before they trigger a desk rejection at this level.

For current APC amounts, visit the Lancet Group open access page, and for author guidelines see the Lancet Oncology information for authors.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)

• An institutional Read & Publish agreement covers the fee

• Open access visibility meaningfully benefits your research area

• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense

• A subscription option or green OA (preprint + embargo) satisfies your funder

• Another OA journal with a lower APC would provide similar visibility

For a manuscript-specific signal before you submit, run a Lancet Oncology submission readiness check.

Or see example reports before you finalize.